Thursday, September 5, 2013

GSK's melanoma vaccine, MAGE-A3 fails to extends disease free survival

MAGE-AE which was being evaluated for the treatment of stageIIIB/C melanoma patients in a Phase 3 trial - DERMA has failed to extend the time melanoma patients live without their disease progressing. However the independent data monitoring committe, which is overseeing the trial has unanimously recommended that the trial be continued until the second co-primary endpoint of the DERMA trial is assessed.  The other co-primary endpoint is evaluating whether MAGE-A3 can extend disease free survival in melanoma patients with gene signature positive. The results are expected in 2015.

IDMC has recommended to continue the trial as the current review of data suggests on safety concerns.3

GSK is continuing to evaluate the same investigational MAGE-A3 cancer immunotherapeutic in another independent Phase III study (MAGRIT) in Non Small Cell Lung Cancer (NSCLC) following surgical removal of the primary tumour with first data anticipated in the first half of 2014




Enter your email address:


Delivered by FeedBurner